{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:44:21Z","timestamp":1794685461788,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Emerging multidrug-resistant\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    strains possessing altered\n                    <jats:italic>penA<\/jats:italic>\n                    alleles (encoding penicillin-binding protein 2, PBP2) threaten the utility of ceftriaxone, the last remaining outpatient antibiotic for gonorrhoea treatment, posing a global health emergency. Here we report a benzoxaborinine-based penicillin-binding protein inhibitor series (boro-PBPi) developed to address\n                    <jats:italic>penA<\/jats:italic>\n                    -mediated ceftriaxone resistance. Optimization of boro-PBPi led to the identification of compound 21 (VNRX-14079), which exhibited potent antibacterial activity against multidrug-resistant\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    through high-affinity binding to the PBP2 target. Boro-PBPi\u2013PBP2 complex structures confirmed the covalent interaction of the boron atom with the catalytic residue Ser310 and the importance of the \u03b2\n                    <jats:sub>3<\/jats:sub>\n                    \u2013\u03b2\n                    <jats:sub>4<\/jats:sub>\n                    loop mobility for improved affinity. Boro-PBPi 21 elicits bactericidal activity, a low frequency of resistance, a good safety profile, suitable pharmacokinetic properties and in vivo efficacy in a murine infection model against ceftriaxone-resistant\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    . Boro-PBPi 21 is therefore a promising antigonorrhoea agent poised for further advancement.\n                  <\/jats:p>","DOI":"10.1038\/s41564-026-02309-3","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:02:46Z","timestamp":1775638966000},"page":"1348-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A penicillin-binding protein inhibitor series to target drug-resistant Neisseria gonorrhoeae"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-4286","authenticated-orcid":false,"given":"Tsuyoshi","family":"Uehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Zulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8460-2310","authenticated-orcid":false,"given":"Steven A.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra L.","family":"Chatwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Drager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Emeigh Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Line","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cullen L.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-648X","authenticated-orcid":false,"given":"Gopinath","family":"Rongala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0737-3209","authenticated-orcid":false,"given":"Annie","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4717-8167","authenticated-orcid":false,"given":"Fan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-795X","authenticated-orcid":false,"given":"Caleb M.","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeepchowdary","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Tkavc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-3172","authenticated-orcid":false,"given":"Ann E.","family":"Jerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Pevear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis M.","family":"Daigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8536-4378","authenticated-orcid":false,"given":"Stephen M.","family":"Condon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2309_CR1","unstructured":"Gonorrhoea (Neisseria gonorrhoeae Infection), (World Health Organization, 2023) https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/gonorrhoea-(neisseria-gonorrhoeae-infection)"},{"key":"2309_CR2","unstructured":"Multi-drug Resistant Gonorrhoea (World Health Organization, 2023); https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multi-drug-resistant-gonorrhoea"},{"key":"2309_CR3","doi-asserted-by":"publisher","first-page":"e1002344","DOI":"10.1371\/journal.pmed.1002344","volume":"14","author":"T Wi","year":"2017","unstructured":"Wi, T. et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med. 14, e1002344 (2017).","journal-title":"PLoS Med."},{"key":"2309_CR4","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/cid\/ciy271","volume":"67","author":"EW Hook III","year":"2018","unstructured":"Hook, E. W. III & Kirkcaldy, R. D. A brief history of evolving diagnostics and therapy for gonorrhea: lessons learned. Clin. Infect. Dis. 67, 1294\u20131299 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"2309_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"M Unemo","year":"2019","unstructured":"Unemo, M. et al. Gonorrhoea. Nat. Rev. Dis. Primers 5, 79 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2309_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03507-23","volume":"12","author":"KM Frost","year":"2024","unstructured":"Frost, K. M. et al. Rolling the evolutionary dice: Neisseria commensals as proxies for elucidating the underpinnings of antibiotic resistance mechanisms and evolution in human pathogens. Microbiol. Spectr. 12, e03507-23 (2024).","journal-title":"Microbiol. Spectr."},{"key":"2309_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101181","volume":"6","author":"M Unemo","year":"2025","unstructured":"Unemo, M. et al. WHO global gonococcal antimicrobial surveillance programmes, 2019\u201322: a retrospective observational study. Lancet Microbe 6, 101181 (2025).","journal-title":"Lancet Microbe"},{"key":"2309_CR8","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","volume":"69","author":"S St. Cyr","year":"2020","unstructured":"St. Cyr, S. et al. Update to CDC\u2019s treatment guidelines for gonococcal infection. MMWR Morb. Mortal. Wkly Rep. 69, 1911\u20131916 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2309_CR9","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S1473-3099(23)00479-6","volume":"23","author":"V Ouk","year":"2023","unstructured":"Ouk, V. et al. The enhanced gonococcal surveillance programme, Cambodia. Lancet Infect. Dis. 23, e332\u2013e333 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"2309_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","volume":"22","author":"JS Jensen","year":"2024","unstructured":"Jensen, J. S. & Unemo, M. Antimicrobial treatment and resistance in sexually transmitted bacterial infections. Nat. Rev. Microbiol. 22, 435\u2013450 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"2309_CR11","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.vaccine.2013.08.067","volume":"32","author":"AE Jerse","year":"2014","unstructured":"Jerse, A. E., Bash, M. C. & Russell, M. W. Vaccines against gonorrhea: current status and future challenges. Vaccine 32, 1579\u20131587 (2014).","journal-title":"Vaccine"},{"key":"2309_CR12","unstructured":"Antibiotic Resistance Threats in the United States, 2019 (US Department of Health and Human Services, Centers for Disease Control and Prevention; 2019)."},{"key":"2309_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18, 318\u2013327 (2018).","journal-title":"Lancet Infect Dis"},{"key":"2309_CR14","unstructured":"WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance (World Health Organization, 2024)."},{"key":"2309_CR15","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S1473-3099(23)00785-5","volume":"24","author":"JL Reimche","year":"2024","unstructured":"Reimche, J. L. et al. Novel strain of multidrug non-susceptible Neisseria gonorrhoeae in the USA. Lancet Infect. Dis. 24, e149\u2013e151 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2309_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/22221751.2021.2011618","volume":"11","author":"X Lin","year":"2022","unstructured":"Lin, X. et al. Dissemination and genome analysis of high-level ceftriaxone-resistant penA 60.001 Neisseria gonorrhoeae strains from the Guangdong gonococcal antibiotics susceptibility Programme (GD-GASP), 2016\u20132019. Emerg. Microbes Infect. 11, 344\u2013350 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"2309_CR17","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/jac\/dkz129","volume":"74","author":"K Lee","year":"2019","unstructured":"Lee, K. et al. Clonal expansion and spread of the ceftriaxone-resistant Neisseria gonorrhoeae strain FC428, identified in Japan in 2015, and closely related isolates. J. Antimicrob. Chemother. 74, 1812\u20131819 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"2309_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3201\/eid2404.171873","volume":"24","author":"MM Lahra","year":"2018","unstructured":"Lahra, M. M. et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg. Infect. Dis. 24, 735\u2013740 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"2309_CR19","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1128\/AAC.00504-16","volume":"60","author":"S Nakayama","year":"2016","unstructured":"Nakayama, S. et al. New ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan. Antimicrob. Agents Chemother. 60, 4339\u20134341 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2309_CR20","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.15585\/mmwr.mm6949a5","volume":"69","author":"MA Picker","year":"2020","unstructured":"Picker, M. A. et al. Notes from the field: first case in the United States of Neisseria gonorrhoeae harboring emerging mosaic penA60 allele, conferring reduced susceptibility to cefixime and ceftriaxone. MMWR Morb. Mortal. Wkly Rep. 69, 1876\u20131877 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2309_CR21","doi-asserted-by":"publisher","first-page":"e01963","DOI":"10.1128\/AAC.01963-19","volume":"64","author":"JC Hamrick","year":"2020","unstructured":"Hamrick, J. C. et al. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 64, e01963\u201301919 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2309_CR22","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","volume":"63","author":"B Liu","year":"2020","unstructured":"Liu, B. et al. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections. J. Med. Chem. 63, 2789\u20132801 (2020).","journal-title":"J. Med. Chem."},{"key":"2309_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00552-21","volume":"65","author":"CL Chatwin","year":"2021","unstructured":"Chatwin, C. L. et al. Microbiological characterization of VNRX-5236, a broad-spectrum \u03b2-lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of Enterobacterales expressing extended-spectrum \u03b2-lactamases and serine carbapenemases. Antimicrob. Agents Chemother. 65, e0055221 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2309_CR24","doi-asserted-by":"publisher","first-page":"10155","DOI":"10.1021\/acs.jmedchem.1c00437","volume":"64","author":"RE Trout","year":"2021","unstructured":"Trout, R. E. et al. Discovery of VNRX-7145 (VNRX-5236 etzadroxil): an orally bioavailable \u03b2-lactamase inhibitor for Enterobacterales expressing Ambler class A, C, and D enzymes. J. Med. Chem. 64, 10155\u201310166 (2021).","journal-title":"J. Med. Chem."},{"key":"2309_CR25","doi-asserted-by":"publisher","first-page":"e0258359","DOI":"10.1371\/journal.pone.0258359","volume":"16","author":"V Kumar","year":"2021","unstructured":"Kumar, V. et al. Structural analysis of the boronic acid \u03b2-lactamase inhibitor vaborbactam binding to Pseudomonas aeruginosa penicillin-binding protein 3. PLoS ONE 16, e0258359 (2021).","journal-title":"PLoS ONE"},{"key":"2309_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12406","volume":"7","author":"J Brem","year":"2016","unstructured":"Brem, J. et al. Structural basis of metallo-\u03b2-lactamase, serine-\u03b2-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat. Commun. 7, 12406 (2016).","journal-title":"Nat. Commun."},{"key":"2309_CR27","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","volume":"62","author":"A Krajnc","year":"2019","unstructured":"Krajnc, A. et al. Bicyclic boronate VNRX-5133 inhibits metallo- and serine-\u03b2-lactamases. J. Med. Chem. 62, 8544\u20138556 (2019).","journal-title":"J. Med. Chem."},{"key":"2309_CR28","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1128\/AAC.00093-13","volume":"57","author":"J Tomberg","year":"2013","unstructured":"Tomberg, J., Unemo, M., Ohnishi, M., Davies, C. & Nicholas, R. A. Identification of amino acids conferring high-level resistance to expanded-spectrum cephalosporins in the penA gene from Neisseria gonorrhoeae strain H041. Antimicrob. Agents Chemother. 57, 3029\u20133036 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2309_CR29","doi-asserted-by":"publisher","first-page":"14020","DOI":"10.1074\/jbc.RA119.009942","volume":"294","author":"A Singh","year":"2019","unstructured":"Singh, A., Tomberg, J., Nicholas, R. A. & Davies, C. Recognition of the \u03b2-lactam carboxylate triggers acylation of Neisseria gonorrhoeae penicillin-binding protein 2. J. Biol. Chem. 294, 14020\u201314032 (2019).","journal-title":"J. Biol. Chem."},{"key":"2309_CR30","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1074\/jbc.RA120.012617","volume":"295","author":"A Singh","year":"2020","unstructured":"Singh, A. et al. Mutations in penicillin-binding protein 2 from cephalosporin-resistant Neisseria gonorrhoeae hinder ceftriaxone acylation by restricting protein dynamics. J. Biol. Chem. 295, 7529\u20137543 (2020).","journal-title":"J. Biol. Chem."},{"key":"2309_CR31","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1021\/acsinfecdis.3c00713","volume":"10","author":"JM Turner","year":"2024","unstructured":"Turner, J. M. et al. Ureidopenicillins are potent inhibitors of penicillin-binding protein 2 from multidrug-resistant Neisseria gonorrhoeae H041. ACS Infect. Dis. 10, 1298\u20131311 (2024).","journal-title":"ACS Infect. Dis."},{"key":"2309_CR32","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","volume":"43","author":"LT Hong","year":"2023","unstructured":"Hong, L. T. et al. International consensus recommendations for the use of prolonged-infusion \u03b2-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy 43, 740\u2013777 (2023).","journal-title":"Pharmacotherapy"},{"key":"2309_CR33","doi-asserted-by":"publisher","first-page":"e01644-18","DOI":"10.1128\/AAC.01644-18","volume":"63","author":"KL Connolly","year":"2019","unstructured":"Connolly, K. L. et al. Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model. Antimicrob. Agents Chemother. 63, e01644-18 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2309_CR34","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 11th edn. CLSI standard M07 (Clinical and Laboratory Standards Institute, 2018)."},{"key":"2309_CR35","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/jac\/dkae176","volume":"79","author":"M Unemo","year":"2024","unstructured":"Unemo, M. et al. The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization. J. Antimicrob. Chemother. 79, 1885\u20131899 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"2309_CR36","doi-asserted-by":"publisher","first-page":"1800323","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","volume":"23","author":"DW Eyre","year":"2018","unstructured":"Eyre, D. W. et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill. 23, 1800323 (2018).","journal-title":"Euro Surveill."},{"key":"2309_CR37","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jac\/dkr021","volume":"66","author":"M Liao","year":"2011","unstructured":"Liao, M., Gu, W. M., Yang, Y. & Dillon, J. A. Analysis of mutations in multiple loci of Neisseria gonorrhoeae isolates reveals effects of PIB, PBP2 and MtrR on reduced susceptibility to ceftriaxone. J. Antimicrob. Chemother. 66, 1016\u20131023 (2011).","journal-title":"J. Antimicrob. Chemother."},{"key":"2309_CR38","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1021\/acs.biochem.6b01030","volume":"56","author":"J Tomberg","year":"2017","unstructured":"Tomberg, J. et al. Alanine 501 mutations in penicillin-binding protein 2 from Neisseria gonorrhoeae: structure, mechanism, and effects on cephalosporin resistance and biological fitness. Biochemistry 56, 1140\u20131150 (2017).","journal-title":"Biochemistry"},{"key":"2309_CR39","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.05760-11","volume":"56","author":"M Unemo","year":"2012","unstructured":"Unemo, M. et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob. Agents Chemother. 56, 1273\u20131280 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2309_CR40","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/jac\/dks162","volume":"67","author":"J Camara","year":"2012","unstructured":"Camara, J. et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J. Antimicrob. Chemother. 67, 1858\u20131860 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"2309_CR41","doi-asserted-by":"publisher","first-page":"e01905-17","DOI":"10.1128\/mBio.01905-17","volume":"9","author":"LR Vincent","year":"2018","unstructured":"Vincent, L. R. et al. In vivo-selected compensatory mutations restore the fitness cost of mosaic penA alleles that confer ceftriaxone resistance in Neisseria gonorrhoeae. mBio 9, e01905-17 (2018).","journal-title":"mBio"},{"key":"2309_CR42","first-page":"mgen000480","volume":"6","author":"MN Osnes","year":"2020","unstructured":"Osnes, M. N. et al. Sudden emergence of a Neisseria gonorrhoeae clade with reduced susceptibility to extended-spectrum cephalosporins, Norway. Microb. Genom. 6, mgen000480 (2020).","journal-title":"Microb. Genom."},{"key":"2309_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107101","volume":"63","author":"Y Liao","year":"2024","unstructured":"Liao, Y. et al. penA profile of Neisseria gonorrhoeae in Guangdong, China: novel penA alleles are related to decreased susceptibility to ceftriaxone or cefixime. Int. J. Antimicrob. Agents 63, 107101 (2024).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2309_CR44","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/OLQ.0000000000001031","volume":"46","author":"MM de Laat","year":"2019","unstructured":"de Laat, M. M. et al. Ceftriaxone reduced susceptible Nisseria gonorrhoeae in the Netherlands, 2009 to 2017: from penA mosaicism to a501T\/V nonmosaicism. Sex. Transm. Dis. 46, 594\u2013601 (2019).","journal-title":"Sex. Transm. Dis."},{"key":"2309_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/d41586-023-03448-x","volume":"623","author":"E Callaway","year":"2023","unstructured":"Callaway, E. \u2018Groundbreaking\u2019: first treatment targeting \u2018super-gonorrhoea\u2019 passes trial. Nature 623, 236 (2023).","journal-title":"Nature"},{"key":"2309_CR46","first-page":"239","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. GSK\u2019s first-in-class antibiotic secures another phase III win, approaches regulatory run. Nat. Rev. Drug Discov. 23, 239 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2309_CR47","unstructured":"2021 Antibacterial Agents in Clinical and Preclinical Development: an Overview and Analysis (World Health Organization, 2022); https:\/\/www.who.int\/publications\/i\/item\/9789240047655"},{"key":"2309_CR48","unstructured":"Target Product Profile for Therapy of Diagnosed Uncomplicated Gonorrhoea (World Health Organization, 2020)."},{"key":"2309_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jat.727","volume":"21","author":"KH Diehl","year":"2001","unstructured":"Diehl, K. H. et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol. 21, 15\u201323 (2001).","journal-title":"J. Appl. Toxicol."},{"key":"2309_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101188","volume":"297","author":"BA Fenton","year":"2021","unstructured":"Fenton, B. A. et al. Mutations in PBP2 from ceftriaxone-resistant Neisseria gonorrhoeae alter the dynamics of the \u03b23\u2013\u03b24 loop to favor a low-affinity drug-binding state. J. Biol. Chem. 297, 101188 (2021).","journal-title":"J. Biol. Chem."},{"key":"2309_CR51","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/22221751.2020.1773325","volume":"9","author":"K Zhou","year":"2020","unstructured":"Zhou, K., Chen, S. C., Yang, F., van der Veen, S. & Yin, Y. P. Impact of the gonococcal FC428 penA allele 60.001 on ceftriaxone resistance and biological fitness. Emerg. Microbes Infect. 9, 1219\u20131229 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"2309_CR52","doi-asserted-by":"crossref","unstructured":"Wang, L. C., Litwin, M., Sahiholnasab, Z., Song, W. & Stein, D. C. Neisseria gonorrhoeae aggregation reduces its ceftriaxone susceptibility. Antibiotics 7, 48 (2018).","DOI":"10.3390\/antibiotics7020048"},{"key":"2309_CR53","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1093\/jac\/dkw288","volume":"71","author":"M Unemo","year":"2016","unstructured":"Unemo, M. et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. J. Antimicrob. Chemother. 71, 3096\u20133108 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"2309_CR54","doi-asserted-by":"publisher","first-page":"e00699","DOI":"10.1128\/MRA.00699-20","volume":"9","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. A culture collection of 50 Neisseria gonorrhoeae isolates. Microbiol. Resour. Announc. 9, e00699\u201320 (2020).","journal-title":"Microbiol. Resour. Announc."},{"key":"2309_CR55","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1128\/jcm.32.7.1825-1826.1994","volume":"32","author":"CP Cartwright","year":"1994","unstructured":"Cartwright, C. P., Stock, F. & Gill, V. J. Improved enrichment broth for cultivation of fastidious organisms. J. Clin. Microbiol. 32, 1825\u20131826 (1994).","journal-title":"J. Clin. Microbiol."},{"key":"2309_CR56","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 30th edn. CLSI supplement M100 (Clinical and Laboratory Standards Institute, 2020)."},{"key":"2309_CR57","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 34th edn. CLSI Supplement M100 (Clinical and Laboratory Standards Institute, 2024)."},{"key":"2309_CR58","doi-asserted-by":"publisher","first-page":"7596","DOI":"10.1021\/bi5011317","volume":"53","author":"A Fedarovich","year":"2014","unstructured":"Fedarovich, A., Cook, E., Tomberg, J., Nicholas, R. A. & Davies, C. Structural effect of the Asp345a insertion in penicillin-binding protein 2 from penicillin-resistant strains of Neisseria gonorrhoeae. Biochemistry 53, 7596\u20137603 (2014).","journal-title":"Biochemistry"},{"key":"2309_CR59","doi-asserted-by":"publisher","first-page":"e44918","DOI":"10.1371\/journal.pone.0044918","volume":"7","author":"A Fedarovich","year":"2012","unstructured":"Fedarovich, A. et al. High-throughput screening for novel inhibitors of Neisseria gonorrhoeae penicillin-binding protein 2. PLoS ONE 7, e44918 (2012).","journal-title":"PLoS ONE"},{"key":"2309_CR60","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"2309_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00692-23","volume":"11","author":"S Lopez-Arguello","year":"2023","unstructured":"Lopez-Arguello, S. et al. Penicillin-binding protein occupancy dataset for 18 \u03b2-lactams and 4 \u03b2-lactamase inhibitors in Neisseria gonorrhoeae. Microbiol. Spectr. 11, e0069223 (2023).","journal-title":"Microbiol. Spectr."},{"key":"2309_CR62","doi-asserted-by":"publisher","first-page":"e1012783","DOI":"10.1371\/journal.ppat.1012783","volume":"20","author":"S Lopez-Arguello","year":"2024","unstructured":"Lopez-Arguello, S. et al. Differential contribution of PBP occupancy and efflux on the effectiveness of \u03b2-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. PLoS Pathog. 20, e1012783 (2024).","journal-title":"PLoS Pathog."},{"key":"2309_CR63","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"2309_CR64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"2309_CR65","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"2309_CR66","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1107\/S0907444902016657","volume":"58","author":"PD Adams","year":"2002","unstructured":"Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D 58, 1948\u20131954 (2002).","journal-title":"Acta Crystallogr. D"},{"key":"2309_CR67","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240\u2013255 (1997).","journal-title":"Acta Crystallogr. D"},{"key":"2309_CR68","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1128\/IAI.67.11.5699-5708.1999","volume":"67","author":"AE Jerse","year":"1999","unstructured":"Jerse, A. E. Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. Infect. Immun. 67, 5699\u20135708 (1999).","journal-title":"Infect. Immun."},{"key":"2309_CR69","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1208\/s12248-009-9106-3","volume":"11","author":"L Zhang","year":"2009","unstructured":"Zhang, L., Zhang, Y. D., Zhao, P. & Huang, S. M. Predicting drug\u2013drug interactions: an FDA perspective. AAPS J. 11, 300\u2013306 (2009).","journal-title":"AAPS J."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02309-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02309-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02309-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:15:10Z","timestamp":1778670910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02309-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["2309"],"URL":"https:\/\/doi.org\/10.1038\/s41564-026-02309-3","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.U., A.L.Z., B.M., L.M.A., S.A.B., C.L.C., G.-H.C., A.S.D., M.E., S.G.E.H., N.J.L., C.L.M., G.R., A.S., K.U., F.Y., D.C.P., C.J.B., D.M.D. and S.M.C. are former employees of Venatorx Pharmaceuticals, Inc. T.U., A.L.Z., S.A.B., C.L.C., G.-H.C., N.J.L., C.L.M., D.C.P., C.J.B., D.M.D. and S.M.C. are co-inventors of a patent application covering the molecules described in this manuscript (US20240270762, EP4347607, CN117693511, AU2022279901, CA3219907). D.C.P. is the President and CEO of Spring Mill Pharma, Inc., which currently owns the intellectual property of the boro-PBPi programmes run at Venatorx Pharmaceuticals, Inc. B.W., Z.L., M.W., Z.Z., X.Z. and H.Z. are current or former employees of BioDuro-Sundia. C.M.S., S.B., C.D., R.T. and A.E.J. declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}